References of "Rovati, Lucio C"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailHealth economics in osteoarthritis
Hiligsmann, Mickaël ULg; Cooper, Cyrus; Arden, Nigel et al

in Osteoporosis International (2013, April), 24(Suppl.1), 79-80

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailHealth economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).
Hiligsmann, Mickaël ULg; Cooper, Cyrus; Arden, Nigel et al

in Seminars in Arthritis & Rheumatism (2013), 43(3), 303-313

OBJECTIVES: There is an important need to evaluate therapeutic approaches for osteoarthritis (OA) in terms of cost-effectiveness as well as efficacy. METHODS: The ESCEO expert working group met to discuss ... [more ▼]

OBJECTIVES: There is an important need to evaluate therapeutic approaches for osteoarthritis (OA) in terms of cost-effectiveness as well as efficacy. METHODS: The ESCEO expert working group met to discuss the epidemiological and economic evidence that justifies the increasing concern of the impact of this disease and reviewed the current state-of-the-art in health economic studies in this field. RESULTS: OA is a debilitating disease; it is increasing in frequency and is associated with a substantial and growing burden on society, in terms of both burden of illness and cost of illness. Economic evaluations in this field are relatively rare, and those that do exist, show considerable heterogeneity of methodological approach (such as indicated population, comparator, decision context and perspective, time horizon, modeling and outcome measures used). This heterogeneity makes comparisons between studies problematic. CONCLUSIONS: Better adherence to guidelines for economic evaluations is needed. There was strong support for the definition of a reference case and for what might constitute "standard optimal care" in terms of best clinical practice, for the control arms of interventional studies. [less ▲]

Detailed reference viewed: 17 (6 ULg)
Full Text
Peer Reviewed
See detailTotal joint replacement after glucosamine sulfate treatment of knee osteoarthritis: results from a 8-year prospective cohort
Bruyère, Olivier ULg; Pavelka, K.; Rovati, Lucio C et al

in Osteoporosis International (2007, March), 18(Suppl.1), 81

Detailed reference viewed: 15 (0 ULg)
Full Text
Peer Reviewed
See detailClinical significance of the long-term symptom-modifying effects of glucosamine sulfate: comment on the article by Brandt and Mazzuca
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg; Giacovelli, Giampaolo et al

in Arthritis and Rheumatism (2006), 54(7), 2339-2341

Detailed reference viewed: 14 (6 ULg)
Full Text
Peer Reviewed
See detailResponders to glucosamine sulfate in knee osteoarthritis
Bruyère, Olivier ULg; Pavelka, K.; Richy, Florent et al

in Osteoporosis International (2005, March), 16(Suppl.3), 77

Detailed reference viewed: 8 (3 ULg)
Full Text
Peer Reviewed
See detailResponders to glucosamine sulfate in knee osteoarthritis
Bruyère, Olivier ULg; Pavelka, Karel; Richy, Florent et al

in Arthritis and Rheumatism (2004), 50(suppl.1), 29

Detailed reference viewed: 10 (4 ULg)
Full Text
Peer Reviewed
See detailOsteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate
Christgau, Stephan; Henrotin, Yves ULg; Tanko, Laszlo B et al

in Clinical and Experimental Rheumatology (2004), 22(1, JAN-FEB), 36-42

Objective Glucosamine sulphate has been shown in a large double-blind, placebo-controlled clinical trial to prevent structural damage and improve clinical symptoms of osteoarthritis (OA). We investigated ... [more ▼]

Objective Glucosamine sulphate has been shown in a large double-blind, placebo-controlled clinical trial to prevent structural damage and improve clinical symptoms of osteoarthritis (OA). We investigated whether early response in a newly developed biochemical marker of collagen type II degradation (CTX-II, CartiLaps ELISA) could reflect the long-term preservation of hyaline cartilage. Methods Study subjects comprised 212 knee OA patients participating in a clinical trial of the effects of glucosamine sulphate. Disease symptoms were assessed quarterly by WOMAC scoring and X-ray analysis was performed at baseline and after 3 years. Urine samples were obtained at baseline and after 1, 2 and 3 years for measurement in the CartiLaps assay. The measurements were corrected for creatinine. Results At baseline the patients had an average concentration of urinary CTX-II of 222.4 +/- 159.5 ng/mmol creatinine. This was significantly above the CTX-II levels measured in urine samples from 415 healthy controls (169.1 +/- 92.3 ng/mmol, p < 0.0001). There was no significant difference in the CTX-II response in the placebo group and the glucosamine treated group. However, those with high cartilage turnover presented a significant decrease in CTX-II after 12-month glucosamine treatment. Thus, thee group with CTX II concentrations above normal average + ISD decreased 15.5 % after 12-month therapy. The 12 months change in CTX-II in OA patients with elevated CTX-II at baseline correlated with the change in average joint space width observed after 36 months (R = 0.43, p < 0.05). Increased baseline levels of CTX-II were associated with a worsening of the WOMAC index (p < 0.01). Conclusion The data indicate that measurement of urinary collagen type H C-telopeptide fragments enables the identification of OA patients with high cartilage turnover who at the same time are most responsive to therapy with structure modifying drugs. [less ▲]

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailGlucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies
Bruyère, Olivier ULg; Pavelka, K.; Rovati, Lucio C et al

in Menopause (2004), 11(2), 138-143

OBJECTIVE: To investigate the effect of glucosamine sulfate on long-term symptoms and structure progression in postmenopausal women with knee osteoarthritis (OA). DESIGN: This study consisted of a ... [more ▼]

OBJECTIVE: To investigate the effect of glucosamine sulfate on long-term symptoms and structure progression in postmenopausal women with knee osteoarthritis (OA). DESIGN: This study consisted of a preplanned combination of two three-year, randomized, placebo-controlled, prospective, independent studies evaluating the effect of glucosamine sulfate on symptoms and structure modification in OA and post-hoc analysis of the results obtained in postmenopausal women with knee OA. Minimal joint space width was assessed at baseline and after 3 years from standing anteroposterior knee radiographs. Symptoms were scored by the algo-functional WOMAC index at baseline and after 3 years. All primary statistical analyses were performed in intention-to-treat, comparing joint space width and WOMAC changes between groups by ANOVA. RESULTS: Of 414 participants randomized in the two studies, 319 were postmenopausal women. At baseline, glucosamine sulfate and placebo groups were comparable for demographic and disease characteristics, both in the general population and in the postmenopausal women subset. After 3 years, postmenopausal participants in the glucosamine sulfate group showed no joint space narrowing [joint space change of +0.003 mm (95% CI, -0.09 to 0.11)], whereas participants in the placebo group experienced a narrowing of -0.33 mm (95% CI, -0.44 to -0.22; P < 0.0001 between the two groups). Percent changes after 3 years in the WOMAC index showed an improvement in the glucosamine sulfate group [-14.1% (95%, -22.2 to -5.9)] and a trend for worsening in the placebo group (5.4% (95% CI, -4.9 to 15.7) (P = 0.003 between the two groups). CONCLUSION: This analysis, focusing on a large cohort of postmenopausal women, demonstrated for the first time that a pharmacological intervention for OA has a disease-modifying effect in this particular population, the most frequently affected by knee OA. [less ▲]

Detailed reference viewed: 18 (3 ULg)
Full Text
Peer Reviewed
See detailOne-year increase of Coll 2-1 level in urine is predictive of OA progression
Henrotin, Yves ULg; Deberg, Michelle ULg; Labasse, Alain ULg et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 12

Detailed reference viewed: 17 (7 ULg)
Full Text
Peer Reviewed
See detailRelief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure modifying drug trials
Pavelka, K.; Bruyère, Olivier ULg; Rovati, Lucio C et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 62-63

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailFive-year follow-up patients issued from a previous 3-year randomised, controlled trial of glucosamine sulfate in knee osteoarthritis
Bruyère, Olivier ULg; Compère, S.; Gathy, C. et al

in Osteoporosis International (2003, November), 14(Suppl 7), 9

Detailed reference viewed: 16 (5 ULg)
Full Text
Peer Reviewed
See detailFive-year follow-up of patients from a previous 3-year randomised, controlled trial of glucosamine sulfate in knee osteoarthritis
Bruyère, Olivier ULg; Compere, S.; Rovati, Lucio C et al

in Osteoarthritis and Cartilage (2003, October), 11(Suppl.1), 10-11

Detailed reference viewed: 19 (1 ULg)
Full Text
Peer Reviewed
See detailRelief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials
Pavelka, K.; Bruyère, Olivier ULg; Rovati, Lucio C et al

in Osteoarthritis and Cartilage (2003), 11(10), 730-737

Objective: To assess whether improvement in knee pain biased the determination of the structure-modifying effect reported for glucosamine sulfate in two recent 3-year, randomised, placebo-controlled ... [more ▼]

Objective: To assess whether improvement in knee pain biased the determination of the structure-modifying effect reported for glucosamine sulfate in two recent 3-year, randomised, placebo-controlled clinical trials, in which conventional standing antero-posterior full extension knee radiographs were used for the measurement of joint space narrowing, and in which pain relief might have improved knee full extension. Design: Patients completing the 3-year treatment course were selected based on a WOMAC pain decrease at least equal to the mean improvement in the glucosamine sulfate arms in either of the original studies, irrespective of treatment with glucosamine sulfate or placebo (drug responders or placebo responders). In a second approach, 3-year completers were selected if their baseline standing knee pain (item #5 of the WOMAC pain scale) was 'severe' or 'extreme' and improved by any degree at the end of the trials. In both cases, changes in minimum joint space width were compared between treatment groups. Results: Global knee pain was rnild-to-moderate in the two study populations and in all patient subsets identified. There were obviously more pain improvers in the glucosamine sulfate subsets (N=76 in the two studies combined) than in the placebo subsets (N=57), but WOMAC pain scores improved to the same extent, which was as large as over 50% relative to baseline. Nevertheless, the placebo subsets in both studies underwent an evident mean (SD) joint space narrowing, which in the pooled analysis of both studies was -0.22 (0.80) mm, and was not observed with glucosamine sulfate: +0.15 (0.60) mm (P=0.003 vs placebo). Similar results were found in the smaller subsets with greater than or equal to severe baseline standing knee pain that improved after 3 years, with a joint space narrowing nevertheless of -0.28 (0.76) mm with placebo (N=26), not observed with glucosamine sulfate: +0.21 (0.68) mm (N=31; P=0.014 vs placebo). Conclusions: Knee pain relief did not bias the report of a structure-modifying effect of glucosamine sulfate in two recent long-term trials using conventional standing antero-posterior radiographs, possibly due to the mild-to-moderate patient characteristics. (C) 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved. [less ▲]

Detailed reference viewed: 37 (2 ULg)
Full Text
Peer Reviewed
See detailFive-year follow-up of patients from a previous 3-year randomised, controlled trial of glucosamine sulfate in knee osteoarthritis
Bruyère, Olivier ULg; Compere, Stephanie; Rovati, Lucio C et al

in Arthritis and Rheumatism (2003, September), 48(number 9 (suppl.)), 80

Detailed reference viewed: 27 (0 ULg)
Full Text
Peer Reviewed
See detailBiochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis
Bruyère, Olivier ULg; COLLETTE, Julien ULg; Ethgen, Olivier ULg et al

in Journal of Rheumatology (2003), 30(5), 1043-50

OBJECTIVE: To investigate the relationship between biochemical markers of bone and cartilage remodeling and severity or progression (symptoms and structure) of knee osteoarthritis (OA). METHODS: Mean and ... [more ▼]

OBJECTIVE: To investigate the relationship between biochemical markers of bone and cartilage remodeling and severity or progression (symptoms and structure) of knee osteoarthritis (OA). METHODS: Mean and minimal joint space width (JSW) of the femorotibial joint were measured from standardized radiographs taken at baseline and at the end of a 3-year longitudinal study of patients with knee OA. Pain, stiffness, and physical function subscales of the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index were assessed at the same time points. Biochemical markers [serum keratan sulfate (KS), serum hyaluronic acid (HA), urine pyridinoline (PYD) and deoxypyridinoline (DPD), serum osteocalcin (OC), cartilage oligomeric matrix protein (COMP)] were assessed at baseline and after 1 year. RESULTS: At baseline, no significant correlations were observed between values of biochemical markers and JSW or any of the WOMAC scores. Baseline markers were not correlated with 3-year percentage changes observed in mean or minimal JSW and WOMAC scores. Changes observed after 1 year in OC and HA were significantly correlated with 3-year progression in mean JSW (r = -0.24, p = 0.04 and r = 0.27, p = 0.02, respectively) and in minimal JSW (r = -0.31, p = 0.01 and r = 0.24, p = 0.04, respectively). In patients from the lowest quartile of 1-year changes in HA (< -21.22 ng/ml), mean JSW decreased after 3 years by 0.76 (1.23) mm compared to an increase of 0.11 (0.83) mm in patients in the highest quartile (> +14.34 ng/ml) (p = 0.03). CONCLUSION: The 3-year radiological progression of knee OA could be predicted by a 1-year increase in OC or a 1-year decrease in HA levels. [less ▲]

Detailed reference viewed: 15 (5 ULg)
Full Text
Peer Reviewed
See detailImpact of the joint space width measurement method on the design of knee osteoarthritis studies.
Bruyère, Olivier ULg; Henrotin, Yves ULg; Honore, Aline et al

in Aging Clinical & Experimental Research (2003), 15(2), 136-41

BACKGROUND AND AIMS: Recent guidelines recommend measurement of articular loss over several years, determined by conventional X-rays, as the principal outcome measure in clinical trials of potential ... [more ▼]

BACKGROUND AND AIMS: Recent guidelines recommend measurement of articular loss over several years, determined by conventional X-rays, as the principal outcome measure in clinical trials of potential structure-modifying drugs in osteoarthritis (OA). The aim of this study was to assess the impact of the joint space width measurement method on sample size calculation in knee OA studies. METHODS: Standard knee X-rays were taken in 212 patients with knee OA at baseline and after 3 years of follow-up. Mean joint space width (JSW) was measured with an in-house computer-assisted method. Minimum JSW, measured with a graduated magnifying lens, was taken as external standard. After calculation of the intra- and inter-observer reproducibility of the JSW, sensitivity to change was assessed using the standardized response mean (SRM). The number of patients needed to identify a mean significant difference of 0.5 mm in joint space narrowing between the placebo and the treated group, after 3 years of follow-up, was then calculated. RESULTS: JSW measured with the computer-assisted technique showed better intra- and inter-observer reproducibility than when using the magnifying lens. JSW values measured with our computer-assisted method were significantly correlated with JSW values obtained using the magnifying lens (r=0.87, p<0.001). The SRM were 0.44 and 0.40 for the computer-assisted method and magnifying lens, respectively. The number of patients needed was 131 per group using the computer-assisted method, and 104 using the magnifying lens. CONCLUSIONS: Our method of measurement of JSW may be of potential use in longitudinal studies evaluating the effect of structure-modifying drugs in OA, due to its high level of precision and efficiency. However, although sensitivity to change is markedly better with the digitized method compared with the graduated magnifying lens, we recommend the measurement of mean and minimum JSW in structure-modifying OA trials. [less ▲]

Detailed reference viewed: 63 (17 ULg)
Full Text
Peer Reviewed
See detailCorrelation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate.
Bruyère, Olivier ULg; Honore, Aline; Ethgen, Olivier ULg et al

in Osteoarthritis and Cartilage (2003), 11(1), 1-5

OBJECTIVE: To investigate the relationship between baseline radiographic severity of knee osteoarthritis (OA) and the importance of long-term joint space narrowing. DESIGN: Sub-analysis from a three-year ... [more ▼]

OBJECTIVE: To investigate the relationship between baseline radiographic severity of knee osteoarthritis (OA) and the importance of long-term joint space narrowing. DESIGN: Sub-analysis from a three-year randomized, placebo-controlled, prospective study, of 212 patients with knee OA, recruited in an osteoarthritic outpatient clinic and having been part of a study evaluating the effect of glucosamine sulfate on symptom and structure modification in knee OA. MATERIAL AND METHODS: Measurements of mean joint space width (JSW), assessed by a computer-assisted method, were performed at baseline and after 3 years, on weightbearing anteroposterior knee radiographs. RESULTS: In the placebo group, baseline JSW was significantly and negatively correlated with the joint space narrowing observed after 3 years (r=-0.34, P=0.003). In the lowest quartile of baseline mean JSW (<4.5mm), the JSW increased after 3 years by (mean (S.D.)) 3.8% (23.8) in the placebo group and 6.2% (17.5) in the glucosamine sulfate group. The difference between the two groups in these patients with the most severe OA at baseline was not statistically significant (P=0.70). In the highest quartile of baseline mean JSW (>6.2mm), a joint space narrowing of 14.9% (17.9) occurred in the placebo group after 3 years while patients from the glucosamine sulfate group only experienced a narrowing of 6.0% (15.1). Patients with the most severe OA at baseline had a RR of 0.42 (0.17-1.01) to experience a 0.5mm joint space narrowing over 3 years, compared to those with the less affected joint. In patients with mild OA, i.e. in the highest quartile of baseline mean JSW, glucosamine sulfate use was associated with a trend (P=0.10) towards a significant reduction in joint space narrowing. CONCLUSION: These results suggest that patients with the less severe radiographic knee OA will experience, over 3 years, the most dramatic disease progression in terms of joint space narrowing. Such patients may be particularly responsive to structure-modifying drugs. [less ▲]

Detailed reference viewed: 34 (3 ULg)
Full Text
Peer Reviewed
See detailClinical severity of knee osteoarthritis poorly predicts long-term radiographic outcomes
Bruyère, Olivier ULg; Ethgen, Olivier ULg; Lejeune, Eric ULg et al

in Osteoporosis International (2002, November), 13(Suppl.3), 51

Detailed reference viewed: 4 (1 ULg)
Full Text
Peer Reviewed
See detailPain relief is not a confounder in joint space narrowing assessment of full extension knee radiographs in osteoarthritis structure-modifying drug trials
Pavelka, K.; Rovati, Lucio C; Gatterova, J. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 19-20

Detailed reference viewed: 10 (2 ULg)